Latest Breaking News On - Novel therapies - Page 5 : comparemela.com

Global Electroceuticals / Bioelectric Medicine Strategic

Global Electroceuticals / Bioelectric Medicine Strategic
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Age group in millionDevelopment of new bioelectronic devicesAxonics modulation technologies incElectroceutical technology to treat pain injuryEndonovo therapeutics incNeuronetics incMicroport scientific corporationAge groupCochlear ltdNu eyne companyBioelectronics corporationCo ltdBiowave corporationAbbott laboratories incBioelectric medicineStrategic business

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients blood compared to baseline that was also much larger than a.

United statesSan franciscoJonathan nugentLewish benderMerck sharpe dohmeBristol myers squibbAngel arnaoutDavid rosenSangeetha reddyIntensity therapeutics incOttawa hospital research instituteUniversity of ottawaPrnewswire intensity therapeutics incOntario institute of cancer researchUt southwestern medical centerOntario institute for cancer research network

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.

United statesSan franciscoAngel arnaoutBristol myers squibbSangeetha reddyMerck sharpe dohmeJonathan nugentDavid rosenIntensity therapeutics incNational cancer instituteVaccine branchOntario institute of cancer researchCompany on twitter intensityincUt southwestern medical centerDevelopment agreementOttawa hospital research institute

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the.

United statesJulie rathbunSharay settiMark littonAthira pharmaWei wuWaltere washington convention centerDrug administrationDevelopment of novel therapies for neurodegenerativeSociety for neuroscienceClinical development pipeline programsSecurities exchangeAlzheimer association international conferenceAthira pharma incDevelopment rd expensesExchange commission

KORU Medical Systems, Inc Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook

.

Ken millerLinda tharbyManufacturing initiative expensesInternational coreSystems incReconciliations of the companyNovel therapiesInfusion systemChief commercial officerDomestic coreQuarter financialMonths ended septemberFull yearDiluted earnings perSyringe infusion driversPrecision flow rate tubing